Home / Intelligence / Blog / AI-Based Software Paige Prostate is Granted FDA Approval Through the De Novo Regulatory Pathway
Published September 27, 2021
Paige Prostate is the first artificial intelligence (AI)-based software designed to identify areas of concern (i.e., high likelihood of containing cancer) on a prostate biopsy image so they can be flagged for further review by a pathologist. The program is intended to be used as an adjunct tool to the review of digital scanner slide images from prostate biopsies.
The program was reviewed through the De Novo pathway, a regulatory pathway for low-to-moderate risk novel devices. The FDA authorization is based on clinical trial data which suggests improved detection of cancer on slide images by an average of 7.3% with Paige Prostate vs. unassisted examination by pathologists. The program also reduced the number of false-negatives by 70% and false-positives by 24%. This FDA authorization follows Paige AI receiving a CE mark for both its prostate software and its breast cancer product for use in the EU last year.
Paige’s co-founder and chief medical officer, David Klimstra, notes that Paige’s landmark FDA-approval and EU access “marks the beginning of a new era in the use of computer-assisted diagnostics for pathology.”
Written by Crystal Zhao and Kate Watkins
Related Intelligence
Webinars
The GenAI Advantage: Empowering Pharma Customer-Facing Teams
June 11, 2025 | 1:00 – 1:45 PM ET
Additional sessions will be offered on:June 12 – 12:00 (UTC +8:00) – Asia/ShanghaiJune 12 – 12:00 CET – Europe/Berlin Join us for the first webinar in our “AI Innovations in Life Sciences” series to learn how generative AI (GenAI) can transform the way customer-facing teams (sales reps and medical science liaisons) operate in life sciences […]
Sign Up Now
White Papers
Technology with a Point of View: Encoding Life Sciences Expertise with AI
As an industry, life sciences is now looking towards technological change to leverage investments made during the past few years. In fact, according to Trinity’s TGaS Advisors, the proportion of surveyed companies reporting that they have completed proof of concept or are using GenAI at an enterprise level for commercial, medical, or customer operations surged […]
Read More
Webinars
Generative AI in Pharma – Five Years From Now
Available On Demand
Generative AI is having a transformative impact on the pharmaceutical industry. Drugmakers are partnering up with companies like Insilico Medicine, Exscientia, BenevolentAI, and more to leverage their respective generative AI-powered platforms and applying them across the pharma value chain: from accelerating drug discovery and optimizing clinical trials, to improving operational efficiencies and enabling personalized treatments […]
Watch Now